John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Sasane R, Mitra D, Hodgkins P, Davis KL. Childhood ADHD in Europe: a comparison of patient and physician profiles across countries. Poster presented at the 23rd ECNP Congress; August 2010. [abstract] Eur Neuropsychopharmacol. 2010 Aug; 20(Suppl. 3):S616-7.
Mitra D, Sasane R, Hodgkins P, Davis KL. Management of ADHD among children in Europe: a comparison of practice patterns across countries. Poster presented at the 23rd ECNP Congress; August 2010. [abstract] Eur Neuropsychopharmacol. 2010 Aug; 20(Suppl. 3):S625-6.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Williams VSL, Fehnel SE, Hollis KA, Hogue SL. Antidepressant induced sexual dysfunction in Europe: a preliminary investigation. Eur Neuropsychopharmacol. 2004 Jan 1;14:S180.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.